In a world where AI and tech are reshaping industries from healthcare to finance, finding the right training can feel like searching for a needle in a digital ...

ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built.

The ALX Pathway programme connects Senior High School (SHS) graduates with top universities by providing scholarships and helping them develop the skills needed for careers in technology and ...

--ALX Oncology Holdings Inc.,, a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will ...

SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies ...

Jason Lettmann, Chief Executive Officer at ALX Oncology, will provide opening and closing remarks, highlighting progress and upcoming milestones for the company's evorpacept clinical program.